Evidence map›Paper›PMID 40699660›Full record

ReviewCurrent issues in molecular biology2025

Ameloblastic Carcinoma: A 40-Year Scoping Review of the Literature.

Maria Giulia Cristofaro, Ida Barca, Angelo R Sottile, Francesco Ferragina

Abstract readReview
In one paragraph

Review in Current issues in molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Maria Giulia CristofaroMaxillo-Facial Surgery Unit, Department of Experimental and Clinical Medicine, "Magna Graecia" University, Viale Europa, 88100 Catanzaro, Italy.ORCID 0000-0002-6365-8518
Ida BarcaMaxillo-Facial Surgery Unit, Department of Experimental and Clinical Medicine, "Magna Graecia" University, Viale Europa, 88100 Catanzaro, Italy.ORCID 0000-0003-3182-5075
Angelo R SottileMaxillo-Facial Surgery Unit, Department of Experimental and Clinical Medicine, "Magna Graecia" University, Viale Europa, 88100 Catanzaro, Italy.
Francesco FerraginaMaxillo-Facial Surgery Unit, Department of Experimental and Clinical Medicine, "Magna Graecia" University, Viale Europa, 88100 Catanzaro, Italy.ORCID 0000-0002-2522-7768

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAmeloblastic carcinoma (AC) is a rare malignant odontogenic tumor with limited knowledge surrounding its pathogenesis, molecular pathways, clinical behavior, treatment, and prognosis. This 40-year literature scoping review aims to enhance the comprehension of this complex condition, looking closely at how AC works at molecular and pathophysiological levels and what causes it to develop.

methodsThe PUBMED, Medline, Scopus, and Cochrane central databases were searched, including articles from 1984 to date. Articles reporting epidemiological, clinical, instrumental, and histopathological data were included.

resultsOut of the 375 articles examined, 52 met the inclusion criteria, yielding a total of 80 cases of AC. All cases before 1984 were excluded from the analysis, as were all that did not provide information on patient survival. Several molecular mechanisms associated with its development and progression were identified; these help in early diagnosis. Moreover, AC can spread locally, making a radical surgical approach necessary. There is still no agreement on how to manage neck dissection. Surgical removal followed by monitoring is an important part of managing AC.

conclusionsAdvancements in biological and molecular insights have the potential to facilitate earlier diagnosis and treatment. These could lead to improvements in patients' quality of life and long-term survival.

Indexed as

ameloblastic carcinomahead and neck cancermaxillofacial surgeryodontogenic tumorsoral health

Identifiers

PMID40699660
PMCPMC12025990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.